Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deudextromethorphan - Avanir Pharmaceuticals

Drug Profile

Deudextromethorphan - Avanir Pharmaceuticals

Alternative Names: AVP-786; CTP-786; d-DM; Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]; Deuterated dextromethorphan plus ultra low dose quinidine; Deuterated DM plus ultra low dose quinidine; Deuterated-dextromethorphan; Deuterated-DM

Latest Information Update: 30 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Concert Pharmaceuticals
  • Developer Avanir Pharmaceuticals
  • Class Antidepressants; Antipsychotics; Antitussives; Morphinans; Neuroprotectants; Opioid analgesics; Organic deuterium compounds; Small molecules
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; KATP channel inhibitors; NMDA receptor antagonists; Norepinephrine plasma membrane transport protein inhibitors; Serotonin plasma membrane transport protein inhibitors; Sigma-1 receptor agonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Agitation
  • Phase II/III Schizophrenia
  • Phase II Brain injuries; Impulse control disorders; Major depressive disorder; Neurodegenerative disorders
  • No development reported Neuropathic pain; Psychiatric disorders

Most Recent Events

  • 12 Nov 2019 Avanir Pharmaceuticals plans an additional phase-III trial for deudextromethorphan in 2020
  • 27 Sep 2019 Adverse events data from the phase III TRIAD-2 in Agitation in patients with dementia of the Alzheimer's type (In adults, In the elderly) released by Avanir Pharmaceuticals
  • 09 Sep 2019 Avanir Pharmaceuticals completes the phase III TRIAD-2 trial in Agitation in patients with dementia of the Alzheimer's type (In adults, In the elderly) in USA and Canada (PO, Capsule) (NCT02442778)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top